These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings

Core Insights - Quest Diagnostics Incorporated reported better-than-expected first-quarter earnings with earnings of $2.21 per share, surpassing the analyst consensus estimate of$2.15 per share [1] - The company achieved quarterly sales of $2.65 billion, exceeding the analyst consensus estimate of$2.63 billion [1] Financial Performance - In the first quarter, Quest Diagnostics experienced strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, attributed to demand recovery in March [2] - The growth was driven by contributions from acquisitions, large enterprise accounts, demand for advanced diagnostics, and expanded health plan access [2] - The company reaffirmed its 2025 revenue guidance of $10.70 billion to$10.85 billion, compared to the consensus of $10.78 billion, and adjusted EPS guidance of$9.55 to $9.80, against the consensus of$9.68 [2] Stock Performance - Following the earnings announcement, Quest Diagnostics shares fell 0.1% to trade at $172.71 [3] - Analysts adjusted their price targets for Quest Diagnostics after the earnings report [3] Analyst Ratings - Baird analyst Eric Coldwell maintained an Outperform rating and raised the price target from$191 to $194 [7] - Evercore ISI Group analyst Elizabeth Anderson maintained an In-Line rating and increased the price target from$175 to $180 [7] - Barclays analyst Stephanie Davis maintained an Equal-Weight rating and raised the price target from$175 to $185 [7] - Truist Securities analyst David Macdonald maintained a Hold rating and increased the price target from$182 to $190 [7]